General description
A cell-permeable, reversible, substrate competitive, and specific inhibitor of insulin-like growth factor-1 (IGF-1) and insulin receptor kinases with significantly lower IC50 values for IGF-1 than for insulin receptors. Induces apoptosis by downregulating the expression of phospho-Akt1 and Bcl-2; and increasing the expression of Bax, p53 and p21. Reported to enhance the radiosensitivity of human breast cancer cells.
A cell-permeable, reversible, substrate competitive, and specific inhibitor of insulin-like growth factor-1 (IGF-1) and insulin receptor tyrosine kinase activity. Exhibits lower IC50 values for IGF-1 than for the insulin receptor. Also inhibits insulin-stimulated cellular proliferation.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
IGF-1
Product does not compete with ATP.
Reversible: yes
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 2 months at -20°C.
Other Notes
Wen, B., et al. 2001. Br. J. Cancer85, 2017.
Parrizas, M., et al. 1997. Endocrinology138, 1427.
Ohmichi, M., et al. 1993. Biochemistry32, 4650.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51111834
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- 121767-1MG
- CAS:
- 65678-07-1
